RALEIGH, N.C., Nov. 13, 2014 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (INC Research) (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced the closing of its previously announced initial public offering (IPO) of shares of its common stock at a price to the public of $18.50 per share. In connection with the IPO, the underwriters exercised in full their option to purchase an additional 1,216,216 shares of common stock from INC Research, bringing the total deal to 9,324,324 shares. Post-IPO, a total of approximately 61,235,000 shares of INC Research common stock are outstanding. The shares sold in the IPO began trading on the NASDAQ Global Select Market under the symbol “INCR” on Nov. 7, 2014.
“The successful completion of our IPO marks an exciting new chapter and phase of growth for INC Research,” said Jamie Macdonald, Chief Executive Officer. “We are pleased with the response we have received to date on our IPO, and look forward to continued collaboration with our biopharmaceutical customers worldwide as we work to accelerate the delivery of new medicines to market for patients in need.”
Goldman, Sachs & Co. and Credit Suisse served as joint lead book-running managers for the offering. Baird, Wells Fargo Securities and William Blair served as co-managers for the offering.
A registration statement relating to these securities has been filed with, and declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
The offering of these securities was made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 866-471-2526, email: prospectus-ny@ny.email.gs.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, phone: 800-221-1037, email: newyork.prospectus@credit-suisse.com.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked “Top CRO to Work With” by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the lack of a prior public market for our stock and potential volatility; our discretion in using the proceeds of the offering; risks associated with our business; and the other risk factors set forth from time to time in our Form S-1 and other SEC filings, copies of which are available free of charge on our website at www.incresearch.com. INC Research assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACT: Investors: Ronnie Speight, +1 919 745 2745 Media: Lori Dorer, +1 513 345 1685
Help employers find you! Check out all the jobs and post your resume.
